TAMIMA MOHAMAD ABOU ARABI
Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Intermittent abdominal pain in IgA vasculitis(2022) BUSCATTI, Izabel Mantovani; SIMON, Juliana Russo; VIANA, Vivianne Saraiva Leitao; ARABI, Tamima Mohamad Abou; TRINDADE, Vitor Cavalcanti; MAIA, Ana Carolina Cortez; MELO, Lara Regina Cavalcante; IHARA, Bianca Pires; AIKAWA, Nadia Emi; SILVA, Clovis ArturObjective: To assess intermittent abdominal pain in IgA vasculitis patients and its relation to demographic data, clinical manifestations and treatments. Methods: A retrospective cohort study included 322 patients with IgA vasculitis (EULAR/PRINTO/PRES criteria) seen at the Pediatric Rheumatology Unit in the last 32 years. Sixteen patients were excluded due to incomplete data in medical charts. Intermittent abdominal pain was characterized by new abdominal pain after complete resolution in the first month of disease. Results: Intermittent abdominal pain was observed in 35/306 (11%) IgA vasculitis patients. The median time between first and second abdominal pain was 10 days (3-30 days). The main treatment of intermittent abdominal pain included glucocorticoid [n=26/35 (74%)] and/or ranitidine [n=22/35 (63%)]. Additional analysis showed that the frequency of intermittent purpura/petechiae (37 vs. 21%; p=0.027) and the median of purpura/petechiae duration [20 (3-90) vs. 14 (1-270) days; p=0.014] were significantly higher in IgA vasculitis patients with intermittent abdominal pain compared to those without. Gastrointestinal bleeding (49 vs. 13%; p<0.001), nephritis (71 vs. 45%; p=0.006), glucocorticoid (74 vs. 44%; p=0.001) and intravenous immunoglobulin use (6 vs. 0%; p=0.036) were also significantly higher in the former group. The frequency of ranitidine use was significantly higher in IgA vasculitis patients with intermittent abdominal pain versus without (63 vs. 28%; p<0.001), whereas the median of ranitidine duration was reduced in the former group [35 (2-90) vs. 60 (5-425) days; p=0.004]. Conclusions:Intermittent abdominal pain occurred in nearly a tenth of IgA vasculitis patients, in the first 30 days of disease, and was associated with other severe clinical features. Therefore, this study suggests that these patients should be followed strictly with clinical and laboratorial assessment, particularly during the first month of disease course.
- Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients(2020) ISLABA, Aline G.; MOTA, Licia M. H.; RIBEIRO, Maria Custodia M.; ARABI, Tamima M.; CIVIDATTI, Georgiana N.; QUEIROZ, Ligia B.; ANDRADE, Danieli C.; SAKAMOTO, Ana P.; TRINDADE, Vitor C.; NOVAK, Glaucia V.; MOLINARI, Beatriz C.; CAMPOS, Lucia M.; AIKAWA, Nadia E.; PEREIRA, Rosa M. R.; TERRERI, Maria T.; MAGALHA, Claudia S.; MARINI, Roberto; GOMES, Hugo R.; SILVA, Marco F.; OLIVEIRA, Sheila K.; SZTAJNBOK, Flavio R.; SACCHETTI, Silvana B.; BICA, Blanca E.; SENA, Evaldo G.; MORAES, Ana P.; SANTOS, Maria C.; ROBAZZI, Teresa C.; SPELLING, Paulo F.; SCHEIBEL, Iloite M.; CAVALCANTI, Andre S.; NAKA, Erica N.; GUIMARAES, Luciano J.; SANTOS, Flavia P.; SAMPAIO, Magda C.; BONFA, Eloisa; SILVA, Clovis A.Objective: To assess childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome(cSLE-APS) in a large Brazilian population. Methods: A retrospective observational cohort study was carried-out in 27 Pediatric Rheumatology university centers, including 1519 cSLE patients. Results: cSLE-APS was observed in 67/1519 (4%) and was diagnosed at disease onset in 39/67 (58%). The median disease duration was 4.9 (0-17) years. Thrombosis recurrences were evidenced in 18/67 (27%) cSLE-APS patients. The most frequent thrombosis sites in cSLE-APS patients were: venous thrombosis in 40/67 (60%), especially deep vein thrombosis in 29/40 (72%); arterial thrombosis in 35/67 (52%), particularly stroke; small vessels thrombosis in 9/67 (13%) and mixed thrombosis in 3/67 (4%). Pregnancy morbidity was observed in 1/67 (1%). Non-thrombotic manifestation associated to cSLE-APS occurred in 21/67 (31%), mainly livedo reticularis in 14/67 (21%), valvar thickening in 4/67 (6%) and valvar vegetations not related to infections in 2/67 (3%). None of them had catastrophic APS. Further analysis demonstrated that the median of SLICC/ACR-DI [1 (0-5) vs. 0(0-7),p < 0.0001] was significantly higher in cSLE-APS patients compared to cSLE without APS. The frequencies of cerebrovascular disease (40% vs. 1%,p < 0.0001), polyneuropathy (9% vs. 1%,p < 0.0001), SLICC/ACR-DI >= 1 (57% vs. 27%, p < 0.0001) and intravenous cyclophosphamide use (59% vs. 37%, p < 0.0001) were significantly higher in the former group. Conclusions: Our large multicenter study demonstrated that cSLE-APS was a rare condition, occurring during disease course with a high accrual damage. Central and peripheral neuropsychiatric involvements were distinctive features of this autoimmune thrombosis.
conferenceObject THE INFLUENCE OF ENVIRONMENTAL FACTORS RELATING TO JUVENILE DERMATOMYOSITIS′S COURSE AND REFRACTORINESS TO TREATMENT(2023) VALOES, Clarissa C. M.; ARABI, Tamima M. A.; BRAGA, Alfesio L. F.; FARHAT, Sylvia C. L.; SALLUM, Adriana M. E.